Literature DB >> 12853693

Development of secondary anaplastic oligoastrocytoma after matched unrelated bone marrow transplantation in a child with acute myeloid leukemia.

Soumya Panigrahi1, Mayukh Das, Dalia Stagler, Shlomi Konstantini, Moshe Gmori, Shimon Slavin, Arnon Nagler.   

Abstract

The growing incidences of secondary malignancies in long-term survivors of childhood leukemia following allogeneic bone marrow transplantation (alloBMT) are increasingly being reported. Among the late complications of conventional myeloablative alloBMT, the occurrence of secondary malignant solid tumors is of major concern. Secondary malignant and benign brain tumors such as astrocytoma, meningioma and glioblastoma have been described in long-term survivors of conventional myeloablative alloBMT. Here we report a case of secondary anaplastic oligoastrocytoma that developed 7 years after matched unrelated alloBMT for relapsing childhood acute myeloid leukemia (AML) with CNS involvement. Although isolated CNS relapse of primary leukemia following alloBMT is not uncommon, it is important to identify and define potential risk factors that may lead to the development of secondary brain tumors in children who received high-dose chemotherapy and irradiation prior to alloBMT presenting with progressive neurological symptoms and to differentiate them from leukemia relapse with CNS involvement. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853693     DOI: 10.1159/000070970

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  2 in total

Review 1.  Secondary oligodendroglioma after postoperative irradiation for medulloblastoma: a case report and review of the literature.

Authors:  Hong-Lin He; Ying-En Lee; Han-Jung Chen; Chao-Tien Hsu; Yu-Yi Huang; I-Wei Chang
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

2.  Secondary anaplastic oligodendroglioma after cranial irradiation: a case report.

Authors:  Aidos Doskaliyev; Fumiyuki Yamasaki; Masahiro Kenjo; Prabin Shrestha; Taiichi Saito; Ryosuke Hanaya; Kazuhiko Sugiyama; Kaoru Kurisu
Journal:  J Neurooncol       Date:  2008-03-29       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.